Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration

Benzinga05-03

After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2432328399?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/9pzGJYJgJ6OClzjGePu7fQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/5e54f1b9e2ec0121c66541f759692a87","is_english":true,"pubTime":"2024-05-03 02:53","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2432328399","market":"us","top_or_hot":-1,"title":"Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration","media":"Benzinga","content":"<div>\n<p>After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-reports-progress-cancer-front-185354262.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMerck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-03 02:53 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/merck-reports-progress-cancer-front-185354262.html><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after...</p>\n\n<a href=\"https://finance.yahoo.com/news/merck-reports-progress-cancer-front-185354262.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739699.SGD","symbol_name":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"https://finance.yahoo.com/news/merck-reports-progress-cancer-front-185354262.html","article_id":"2432328399","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/9pzGJYJgJ6OClzjGePu7fQ--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/5e54f1b9e2ec0121c66541f759692a87"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2432328399","pubTimestamp":1714676034,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Aftertopping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc  just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc  in fighting melanoma.Merck reported improvement in cancer patients receiving its Keytruda regimen.Enrolling698 subjects, the trial evaluated the effect of a treatment that combines Merck’s immunotherapy blockbuster, Keytruda, along with trastuzumab and chemotherapy on patients suffering from gastric or gastroesophageal junction  adenocarcinoma.The final also confirmed thatMerck’sKeytruda combination regimen led to a statistically significant and clinically meaningful improvement, meeting the dual primary endpoint of overall survival.All in all, Merck showed it is making substantial progress in preparing for 2028’s patent expiration of its blockbuster drug, which will likely dent sales. BesidesWinrevair that has been approved in ","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4585":"ETF&股票定投概念","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4139":"生物科技","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2023250843.SGD":"Allianz Thematica Cl AT Acc H2-SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","LU0058720904.USD":"联博国际健康护理基金A","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","BK4501":"段永平概念","BK4588":"碎股","BK4568":"美国抗疫概念","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","MRK":"默沙东","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0861579265.USD":"联博低波幅策略股票基金A","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","LU0122379950.USD":"贝莱德世界健康科学A2","MRNA":"Moderna, Inc.","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","SG9999014542.SGD":"United Income Focus Trust Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","PRGS":"Progress Software Corporation","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","SG9999001176.USD":"United Global Healthcare Acc USD","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU2065732104.USD":"ALLSPRING (LUX) WF GLOBAL SMALL CAP EQUITY \"I\" (USD) ACC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0238689110.USD":"贝莱德环球动力股票基金","BK4532":"文艺复兴科技持仓","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H"},"translate_title":"默克公司报告在癌症方面取得进展，为Keytruda专利到期做准备","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRGS":1,"MRNA":1,"MRK":1},"content_text":"After topping expectations with first quarter revenue and adjusted earnings last week, Merck & Co Inc (NYSE: MRK) just reported encouraging data from its Phase III gastric cancer treatment trial after ending 2023 with good news from its combined treatment with Moderna Inc (NASDAQ: MRNA) in fighting melanoma.\nMerck reported improvement in cancer patients receiving its Keytruda regimen.\nEnrolling 698 subjects, the trial evaluated the effect of a treatment that combines Merck’s immunotherapy blockbuster, Keytruda, along with trastuzumab and chemotherapy on patients suffering from gastric or gastroesophageal junction (GEJ) adenocarcinoma. The final also confirmed that Merck’s Keytruda combination regimen led to a statistically significant and clinically meaningful improvement, meeting the dual primary endpoint of overall survival.\nMerck reported strong first quarter results.\nWith strong sales of its blockbuster immune-based cancer drug, Keytruda, along with vaccine products, Merck reported revenue rose 9% YoY to $15.78 billion, surpassing LSEG’s estimate of $15.20 billion. Net income for the first three months of the year amounted to $4.76 billion, or $1.87 per share. Excluding acquisitions and restructuring costs, adjusted earnings amounted to $2.07 per share, surpassing $1.88 per share that LSEG expected. \nThe pharmaceutical unit reported revenue grew 10% YoY to $14.01 billion, with Keytruda alone bringing in $6.95 billion of those sales as its revenue grew as much as 20% YoY, surpassing even FactSet’s estimate of $6.71 billion. The rise is owed to increased uptake from cancer patients at earliest stages of cancer, along with continued demand for treating metastatic cancers. HPV prevention vaccine, Gardasil, also reported a 14% YoY rise in sales as it brought $2.25 billion to the revenue table. Pneumococcal disease prevention vaccine, Vaxneuvance, also posted remarkable growth of 106% YoY as sales amounted to $219 million.\nOn the other hand, Covid antiviral pill Lagevrio and Type 2 diabetes treatment Januvia, reported sales dropped. Lagevrio reported sales dropped 11% to $350 million, joining the same trend posted by Pfizer and Moderna as COVID-19 now seems to be history. Januvia posted a 24% YoY drop in sales as revenue amounted to $670 million due to falling demand in the U.S., lower prices and generic competition.\nNew deals and drug launches to offset Keytruda’s patent expiration.\nAll in all, Merck showed it is making substantial progress in preparing for 2028’s patent expiration of its blockbuster drug, which will likely dent sales. Besides Winrevair that has been approved in the U.S. last month for treating progressive and life-threatening lung condition. In December, Merck and Moderna presented positive results from the combination of Keytruda and their experimential mRNA vaccine for melanoma, halving relapse risk. Although it was mid-term data from the 3-year follow-up, Merck and Moderna provided hope that mRNA could revolutionize cancer treatment. Moderna director, Stéphane Bancel, hinted that the mRNA vaccine for melanoma could be available as early as 2025. Moreover, after these promising results, Moderna and Merck expanded their research scope to evaluate the effect of the treatment against non-small lung cancer.\nmRNA already saved the world during the unprecedented COVID-19 crisis and now, it promises to do the same with what seems to be pharma’s never-ending health-battle. Keytruda’s patent will expire but Merck did all it can to make sure it continues to contribute to a healthier society. Along with cutting costs under a restructuring program it kicked off in February, Merck is securing its financial existance and future with new deals and promising drug launches.\nDISCLAIMER: This content is for informational purposes only. It is not intended as investing advice.\nThis article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.\n\"ACTIVE INVESTORS' SECRET WEAPON\" Supercharge Your Stock Market Game with the #1 \"news & everything else\" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!\nGet the latest stock analysis from Benzinga?\n\nThis article Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration originally appeared on Benzinga.com\n© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2432328399"}